Menu

Close

Advances in Drug Delivery

Advances in formulation technology or targeted delivery methods that describe or develop the distribution of small molecules or large macromolecules to specific parts of the body.

List by Zhang-He Goh

Preprints:

Engineering Brain Parasites for Intracellular Delivery of Therapeutic Proteins

Shahar Bracha, Karoliina Hassi, Paul D. Ross, Stuart Cobb, Lilach Sheiner, Oded Rechavi

https://www.biorxiv.org/content/10.1101/481192v1

The delivery of drugs across the blood-brain barrier is a challenge to chemists and pharmacologists. In this preprint, Bracha et al. describe an unconventional approach: the authors use engineered brain parasites to achieve directed intracellular therapy of proteins to the central nervous system.

Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies

Candice Gurbatri, Courtney Coker, Taylor E. Hinchliffe, Ioana Lia, Samuel Castro, Piper M. Treuting, Nicholas Arpaia, Tal Danino

https://www.biorxiv.org/content/10.1101/562785v1

For over a decade, the microbiome has attracted the attention of pharmacologists, who have come to recognise the potential role that the microbiome plays in the metabolism and delivery of therapeutics. In this preprint, Gurbatri et al. exploit this interesting feature in bacteria, turning it into a warhead that can deliver immunotherapies–specifically, PD-L1 antagonists.

Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity

S. Pieper, H. Onafuye, D. Mulac, Jindrich Cinatl jr., Mark N. Wass, M. Michaelis, K. Langer

https://www.biorxiv.org/content/10.1101/403923v1

Based on the preliminary results offered by this preprint by Pieper et al., formulators can subject formulations to a more rigorous and systematic process of optimisation over a larger range of conditions, pharmacokineticists can profile the behaviour of these nanoparticle formulations in vitro and in vivo, and, once the effectiveness and safety of these drug delivery systems are demonstrated in animal models, clinician-scientists can run in-human trials on patients who stand to gain from these drug delivery systems.

Categories: pharmacology and toxicology , synthetic biology

 

Posted on: 20th May 2019 , updated on: 5th June 2019

(No Ratings Yet)




  • Have your say

    Your email address will not be published. Required fields are marked *

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Sign up to customise the site to your preferences and to receive alerts

    Register here
    Close